Empowered Funds LLC acquired a new stake in HCA Healthcare, Inc. (NYSE:HCA – Get Rating) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,962 shares of the company's stock, valued at approximately $544,000.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Sivik Global Healthcare LLC grew its holdings in HCA Healthcare by 54.5% in the 3rd quarter. Sivik Global Healthcare LLC now owns 42,500 shares of the company's stock valued at $7,811,000 after buying an additional 15,000 shares during the last quarter. 1ST Source Bank grew its holdings in HCA Healthcare by 2.9% in the 3rd quarter. 1ST Source Bank now owns 8,265 shares of the company's stock valued at $1,519,000 after buying an additional 234 shares during the last quarter. First Pacific Advisors LP grew its holdings in HCA Healthcare by 11.4% in the 3rd quarter. First Pacific Advisors LP now owns 1,225 shares of the company's stock valued at $225,000 after buying an additional 125 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich grew its holdings in shares of HCA Healthcare by 174.4% during the 3rd quarter. Bank Julius Baer & Co. Ltd Zurich now owns 236 shares of the company's stock worth $43,000 after purchasing an additional 150 shares in the last quarter. Finally, Foster & Motley Inc. boosted its stake in HCA Healthcare by 1.5% in the 3rd quarter. Foster & Motley Inc. now owns 28,339 shares of the company's stock valued at $5,209,000 after buying an additional 417 shares in the last quarter. Institutional investors and hedge funds own 64.60% of the company's stock.
Get
HCA Healthcare alerts:
HCA Healthcare Trading Up 0.4 %
NYSE:HCA opened at $253.64 on Thursday. HCA Healthcare, Inc. has a 1 year low of $164.47 and a 1 year high of $279.02. The stock has a market cap of $71.71 billion, a price-to-earnings ratio of 14.33, a PEG ratio of 1.92 and a beta of 1.65. The stock has a 50-day moving average price of $243.73 and a two-hundred day moving average price of $218.48.
Wall Street Analyst Weigh In
HCA has been the topic of several recent analyst reports. Raymond James decreased their price target on HCA Healthcare from $250.00 to $230.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 25th. SVB Leerink boosted their target price on HCA Healthcare from $238.00 to $286.00 and gave the stock an "outperform" rating in a research report on Friday, December 16th. The Goldman Sachs Group boosted their target price on HCA Healthcare from $233.00 to $265.00 and gave the stock a "buy" rating in a research report on Monday, December 12th. Mizuho boosted their target price on HCA Healthcare from $242.00 to $265.00 and gave the stock a "buy" rating in a research report on Wednesday, December 14th. Finally, Stephens dropped their target price on HCA Healthcare from $230.00 to $220.00 and set an "overweight" rating for the company in a research report on Monday, October 24th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, HCA Healthcare has a consensus rating of "Moderate Buy" and a consensus target price of $250.25.
Insider Transactions at HCA Healthcare
In other news, SVP Phillip G. Billington sold 8,332 shares of the company's stock in a transaction dated Friday, October 28th. The stock was sold at an average price of $222.58, for a total transaction of $1,854,536.56. Following the completion of the transaction, the senior vice president now directly owns 40,652 shares of the company's stock, valued at $9,048,322.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Charles J. Hall sold 9,838 shares of the company's stock in a transaction dated Friday, October 28th. The stock was sold at an average price of $223.50, for a total transaction of $2,198,793.00. Following the sale, the insider now owns 199,883 shares in the company, valued at $44,673,850.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phillip G. Billington sold 8,332 shares of the company's stock in a transaction dated Friday, October 28th. The stock was sold at an average price of $222.58, for a total value of $1,854,536.56. Following the sale, the senior vice president now owns 40,652 shares in the company, valued at approximately $9,048,322.16. The disclosure for this sale can be found here. Insiders sold 28,170 shares of company stock valued at $6,294,030 over the last three months. Company insiders own 1.50% of the company's stock.
About HCA Healthcare
(Get Rating)
HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
Read More
- Get a free copy of the StockNews.com research report on HCA Healthcare (HCA)
- AMD Is Still One Of The Best Semiconductor Stocks Out There
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Want to see what other hedge funds are holding HCA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for HCA Healthcare, Inc. (NYSE:HCA – Get Rating).
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
